Loading stock data…
$3.15-0.16 (-4.97%)
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Prime Medicine, Inc. in the Healthcare sector is trading at $3.15 with a market capitalization of $544M. Wall Street consensus targets $7.11 (11 analysts), implying a +125.5% move over the next 12 months. The stock is currently near its 52-week low of $2.67, remaining 9.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.15M↑ | $856,000↑ | $838,000↓ | $1.23M↑ | $1.11M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.28M↑ | -$50.65M↓ | -$48.61M↑ | -$53.97M↓ | -$53.38M |
| Net Income | -$42.11M↑ | -$49.12M↓ | -$46.08M↑ | -$50.58M↑ | -$52.59M |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulom...